Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BVS vs COCH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
BVS Overall Winner
6-Pillar Tally: BVS 5 – 1 COCH
Matrix Metrics: BVS 8 – 2 COCH
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin).
- Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BVS vs COCH
BVS
Head-to-Head Winner
Bioventus Inc. Class A Common Stock
$9.88
-0.7% 1D
Market Cap
$681.3M
TTM Revenue
$586M
Forward P/E
11.1x
Beta / 30D Vol
0.85β · 74% Vol
Unified Composite Score
46.2
HOLD
Tech 35.0
Fund 49.0
Flow 64.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
COCH
Envoy Medical, Inc. Class A Common Stock
$6.70
+0.0% 1D
Market Cap
$51.9M
TTM Revenue
$231,000
Forward P/E
N/M
Beta / 30D Vol
4.94β · 3352% Vol
Unified Composite Score
35.1
SELL
Tech 50.0
Fund 27.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (BVS 5 – 1 COCH)
1. Valuation Multiples
BVS
Forward P/E
11.1x
N/M
Trailing P/E
12.3x
N/M
PEG Ratio
1.20x
N/M
EV / Revenue
1.5x
119.2x
2. Growth & Scale
BVS
Revenue Growth (YoY)
+2.7%
+57.1%
Earnings Growth (YoY)
+69.7%
+0.0%
TTM Revenue (USD)
$586M
$231,000
Market Cap
$681.3M
$51.9M
3. Profitability & Quality
BVS
Gross Margin
68.7%
N/A
Operating Margin
10.1%
-10261.0%
Net Profit Margin
9.8%
0.0%
Return on Equity (ROE)
25.8%
0.0%
4. Balance Sheet & Cash Flow
BVS
Cash Generation (TTM)
$85M
-$21M
Cash Flow Margin
14.5%
N/A
Net Cash / Leverage
$199M Net Debt (0.96x D/E)
$24M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
COCH
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
448.1% (100th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
BVS
OpEx & R&D Intensity
58.6% of Rev ($343M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BVS (8) vs COCH (2)| Institutional Metric | BVS | COCH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $681.3M | $51.9M | BVS | |
| Trailing P/E Ratio | 12.3x | N/M | BVS | |
| Forward P/E Ratio | 11.1x | N/M | BVS | |
| Revenue Growth (YoY) | +2.7% | +57.1% | COCH | |
| Operating Margin (TTM) | 10.1% | -10261.0% | BVS | |
| Net Profit Margin | 9.8% | 0.0% | BVS | |
| Return on Equity (ROE) | 25.8% | 0.0% | BVS | |
| 52-Week Range Position | 36% ($6–$16) | 89% ($0–$7) | COCH | |
| Beta / 30D Volatility | 0.85β · 74% Vol | 4.94β · 3352% Vol | BVS | |
| Unified Institutional Score | 46.2 / 100 (HOLD) | 35.1 / 100 (SELL) | BVS | |
| Trailing 12M Revenue (USD) | $586M | $231,000 | Scale | |
| Gross Profit Margin (TTM) | 68.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.20x PEG · 1.5x EV/Rev | N/M PEG · 119.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $85M ($199M Net Debt (0.96x D/E)) | -$21M ($24M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCH +1058.66 pp
3M Horizon
COCH +827.41 pp
6M Horizon
COCH +838.52 pp
1Y Horizon
COCH +796.38 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BVS Revenue | COCH Revenue | BVS Op. Margin | COCH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $340M | N/A | 9.2% | N/A | BVS |
| FY2020 | $320M | N/A | 6.6% | N/A | BVS |
| FY2021 | $430M | N/A | 2.8% | N/A | BVS |
| FY2022 | $510M | $0M | -32.7% | -3673.4% | BVS |
| FY2023 | $510M | $0M | -16.0% | -5809.8% | BVS |
| FY2024 | $570M | $0M | -2.7% | -8558.2% | BVS |
| FY2025 | $570M | $0M | 9.5% | -9240.7% | BVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BVS
BREAKDOWN
Current IV
448.1%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCH
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BVS Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
58.6% of Rev ($343M)
90D Engineering Disclosures
0 Published
COCH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BVS vs COCH Key Questions & Quantitative Answers
As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas COCH carries 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BVS leads the Growth & Scale pillar: BVS posts +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin), compared with COCH at +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BVS cumulative revenue shifted +67.6% while COCH shifted N/A. In operating R&D and SG&A reinvestment, BVS deploys 58.6% of Rev ($343M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCH.
BVS screens cheaper on headline valuation multiples. BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin), whereas COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BVS (25.8% ROE) versus COCH (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk). By comparison, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCH vs BVS · Reverse Pair
BVS vs AVAH
· Sector Peer
BVS vs ANNX
· Sector Peer
BVS vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking